Potential pharmacogenomic targets in bipolar disorder : considerations for current testing and the development of decision support tools to individualize treatment selection
BACKGROUND: Treatment in bipolar disorder (BD) is commonly applied as a multimodal therapy based on decision algorithms that lack an integrative understanding of molecular mechanisms or a biomarker associated clinical outcome measure. Pharmacogenetics/genomics study the individual genetic variation associated with drug response. This selective review of pharmacogenomics and pharmacogenomic testing (PGT) in BD will focus on candidate genes and genome wide association studies of pharmacokinetic drug metabolism and pharmacodynamic drug response/adverse event, and the potential role of decision support tools that incorporate multiple genotype/phenotype drug recommendations.
MAIN BODY: We searched PubMed from January 2013 to May 2019, to identify studies reporting on BD and pharmacogenetics, pharmacogenomics and PGT. Studies were selected considering their contribution to the field. We summarize our findings in: targeted candidate genes of pharmacokinetic and pharmacodynamic pathways, genome-wide association studies and, PGT platforms, related to BD treatment. This field has grown from studies of metabolizing enzymes (i.e., pharmacokinetics) and drug transporters (i.e., pharmacodynamics), to untargeted investigations across the entire genome with the potential to merge genomic data with additional biological information.
CONCLUSIONS: The complexity of BD genetics and, the heterogeneity in BD drug-related phenotypes, are important considerations for the design and interpretation of BD PGT. The clinical applicability of PGT in psychiatry is in its infancy and is far from reaching the robust impact it has in other medical disciplines. Nonetheless, promising findings are discovered with increasing frequency with remarkable relevance in neuroscience, pharmacology and biology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
International journal of bipolar disorders - 8(2020), 1 vom: 04. Juli, Seite 23 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cuéllar-Barboza, Alfredo B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bipolar disorder |
|---|
| Anmerkungen: |
Date Revised 15.04.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1186/s40345-020-00184-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312101562 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312101562 | ||
| 003 | DE-627 | ||
| 005 | 20231225143704.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40345-020-00184-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1040.xml |
| 035 | |a (DE-627)NLM312101562 | ||
| 035 | |a (NLM)32632502 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cuéllar-Barboza, Alfredo B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potential pharmacogenomic targets in bipolar disorder |b considerations for current testing and the development of decision support tools to individualize treatment selection |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.04.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: Treatment in bipolar disorder (BD) is commonly applied as a multimodal therapy based on decision algorithms that lack an integrative understanding of molecular mechanisms or a biomarker associated clinical outcome measure. Pharmacogenetics/genomics study the individual genetic variation associated with drug response. This selective review of pharmacogenomics and pharmacogenomic testing (PGT) in BD will focus on candidate genes and genome wide association studies of pharmacokinetic drug metabolism and pharmacodynamic drug response/adverse event, and the potential role of decision support tools that incorporate multiple genotype/phenotype drug recommendations | ||
| 520 | |a MAIN BODY: We searched PubMed from January 2013 to May 2019, to identify studies reporting on BD and pharmacogenetics, pharmacogenomics and PGT. Studies were selected considering their contribution to the field. We summarize our findings in: targeted candidate genes of pharmacokinetic and pharmacodynamic pathways, genome-wide association studies and, PGT platforms, related to BD treatment. This field has grown from studies of metabolizing enzymes (i.e., pharmacokinetics) and drug transporters (i.e., pharmacodynamics), to untargeted investigations across the entire genome with the potential to merge genomic data with additional biological information | ||
| 520 | |a CONCLUSIONS: The complexity of BD genetics and, the heterogeneity in BD drug-related phenotypes, are important considerations for the design and interpretation of BD PGT. The clinical applicability of PGT in psychiatry is in its infancy and is far from reaching the robust impact it has in other medical disciplines. Nonetheless, promising findings are discovered with increasing frequency with remarkable relevance in neuroscience, pharmacology and biology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Bipolar disorder | |
| 650 | 4 | |a Pharmacogenetics | |
| 650 | 4 | |a Pharmacogenomic testing | |
| 700 | 1 | |a McElroy, Susan L |e verfasserin |4 aut | |
| 700 | 1 | |a Veldic, Marin |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Balwinder |e verfasserin |4 aut | |
| 700 | 1 | |a Kung, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Romo-Nava, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Nunez, Nicolas A |e verfasserin |4 aut | |
| 700 | 1 | |a Cabello-Arreola, Alejandra |e verfasserin |4 aut | |
| 700 | 1 | |a Coombes, Brandon J |e verfasserin |4 aut | |
| 700 | 1 | |a Prieto, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Betcher, Hannah K |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Katherine M |e verfasserin |4 aut | |
| 700 | 1 | |a Winham, Stacey J |e verfasserin |4 aut | |
| 700 | 1 | |a Biernacka, Joanna M |e verfasserin |4 aut | |
| 700 | 1 | |a Frye, Mark A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of bipolar disorders |d 2013 |g 8(2020), 1 vom: 04. Juli, Seite 23 |w (DE-627)NLM236675591 |x 2194-7511 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2020 |g number:1 |g day:04 |g month:07 |g pages:23 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s40345-020-00184-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2020 |e 1 |b 04 |c 07 |h 23 | ||